Scarica l'app Stockscreener
935.58
1.98%
-18.94
Dopo l'orario di chiusura:
935.98
0.40
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$954.52
Aprire:
$945
Volume 24 ore:
2.72M
Relative Volume:
0.87
Capitalizzazione di mercato:
$835.81B
Reddito:
$65.18B
Utile/perdita netta:
$20.64B
Rapporto P/E:
41.42
EPS:
22.5894
Flusso di cassa netto:
$5.96B
1 W Prestazione:
+4.30%
1M Prestazione:
-8.09%
6M Prestazione:
+14.12%
1 anno Prestazione:
+14.34%
Intervallo 1D:
$930.02
$957.69
Intervallo di 1 settimana:
$877.11
$976.68
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New TreatmentsNews and Statistics - IndexBox
AI Models Split on Eli Lilly (LLY) as Growth Strength Meets Premium Valuation - TipRanks
Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” - Insider Monkey
Eli Lilly (LLY) Is Up 6.5% After FDA Clears Anytime Oral GLP-1 Foundayo for Obesity Treatment - simplywall.st
Jim Cramer Likes Eli Lilly’s (LLY) New Deal - Insider Monkey
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight - The Motley Fool
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight - The Motley Fool
Eli Lilly and Company $LLY Shares Sold by Weatherly Asset Management L. P. - MarketBeat
Frank Rimerman Advisors Boosts Eli Lilly Stock Position - National Today
Mounjaro: Eli Lilly's GLP-1 Powerhouse Driving Weight Loss Revolution and Investor Interest in North - AD HOC NEWS
Eli Lilly and Company $LLY is Tema Etfs LLC's 4th Largest Position - MarketBeat
Elser Financial Planning Boosts Stake in Eli Lilly - National Today
Elser Financial Planning Inc Has $28.18 Million Stake in Eli Lilly and Company $LLY - MarketBeat
How Eli Lilly’s oral GLP-1 could change the obesity drug market - Healthcare Brew
Eli Lilly (LLY) Valuation Check As Foundayo Oral GLP 1 Approval Lifts Obesity Growth Story - simplywall.st
Eli Lilly’s new GLP-1 weight loss pill Foundayo receives FDA approval - InkFreeNews.com
Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill - Insider Monkey
Eli Lilly’s LY4060874 Phase 1 Readout: What a Quiet Pipeline Update Means for LLY Investors - TipRanks
Eli Lilly and Company stock: Foundayo approval ignites 2026 boom? - AD HOC NEWS
To celebrate its anniversary, Eli Lilly marks 150 years of everything else - PRWeek
Should You Be Adding Eli Lilly (NYSE:LLY) To Your Watchlist Today? - 富途牛牛
Novo Nordisk Weight Loss Pill Outperforms Eli Lilly Rival in New Clinical Trial Data - TIKR.com
Nisa Investment Advisors Boosts Stake in Eli Lilly - National Today
3,818 Shares in Eli Lilly and Company $LLY Acquired by Fulcrum Capital LLC - MarketBeat
Nisa Investment Advisors LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Moody Lynn & Lieberson LLC Purchases 2,657 Shares of Eli Lilly and Company $LLY - MarketBeat
Nikulski Financial Inc. Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (LLY) expands Zepbound access as pricing reforms boost long-term growth outlook - MSN
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions - Manufacturing Chemist
Eli Lilly Stock (LLY) Opinions on FDA Approval of Foundayo - Moomoo
Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion - thelec.net
FDA approves Eli Lilly's new weight loss pill with no food restrictions - qz.com
Eli Lilly's Foundayo Pill Approved: Stock Gains, Launch April 6, 2026News and Statistics - IndexBox
Eli Lilly, Novo Nordisk Intensify Competition With Oral Obesity Drugs - thelec.net
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Singapore
Eli Lilly and Company (NYSE:LLY) Shares Down 2%Should You Sell? - MarketBeat
Novo Nordisk: Competing In A Duopoly (TSX:NOVO:CA) - Seeking Alpha
A new weight-loss pill is here, and it could reshape the GLP-1 market - Fast Company
Stocks with rising composite ratings: Eli Lilly - MSN
LLY Stock Quote Price and Forecast - CNN
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Explainer: What to Know About Foundayo, Eli Lilly’s New Once-Daily Weight-Loss Pill - U.S. News & World Report
Doctor shares what to know about new weight-loss pill Foundayo - ABC News
Eli Lilly Stock Surges 3.6% on Strong Trading - National Today
What you need to know about Eli Lilly’s Foundayo weight loss pill - Houston Chronicle
FDA Approves New GLP-1 Weight Loss Pill from Eli Lilly - People.com
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring - FinancialContent
Eli Lilly’s Foundayo Pill Resets Obesity Portfolio And Valuation Debate - simplywall.st
The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval - Scientific American
Eli Lilly launches Zepbound KwikPen on Ro (LLY:NYSE) - Seeking Alpha
Eli Lilly (LLY) Partners with Ro to Launch Zepbound KwikPen Nati - GuruFocus
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.44%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):